Is a lower cholesterol or A1c necessarily better?

Two major events in 2008 tests these assertions.

First, the ENHANCE trial showed that while the combination of simvastatin and ezetimibe lowered cholesterol, it did not slow the progression of atherosclerosis.

Next, the ACCORD study concluded that a hemoglobin A1c target of less than 6% was associated with an increased mortality, ending that particular arm of the trial.

MedPage Today includes these stories among others in their 2008 roundup of top medical stories.

✓ Join 150,000+ subscribers
✓ Get KevinMD's most popular stories